---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-177016"
form_type: "8-K"
ticker: null
cik: "0001305253"
company_name: "Eiger BioPharmaceuticals, Inc."
filed_at: "2024-07-10T23:59:59+00:00"
generated_at: "2026-05-31T21:59:34.701313+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Eiger sells Avexitide to Amylyx for $35.1M in bankruptcy sale closed July 9

## Summary
- Sold Avexitide asset to Amylyx Pharmaceuticals for $35.1M plus assumed cure costs and liabilities.
- Bankruptcy Court approved sale on June 26, 2024; transaction closed July 9, 2024.
- Amylyx will handle development, manufacturing, and commercialization of Avexitide.
- Eiger's common stock (EIGRQ) trades on OTC Pink; company cautions of potential total loss for securityholders.

## SEC filing metadata
- accession: 0001193125-24-177016
- form_type: 8-K
- cik: 0001305253
- company_name: Eiger BioPharmaceuticals, Inc.
- filed_at: 2024-07-10T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 2.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1305253/000119312524177016/0001193125-24-177016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1305253/000119312524177016/d861769d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-177016
- JSON: https://secwatch.observer/filing/0001193125-24-177016.json
- Plain text: https://secwatch.observer/filing/0001193125-24-177016.txt

## Key facts
- M&A Transactions
  Eiger BioPharmaceuticals, Inc. completed a disposition involving Amylyx Pharmaceuticals, Inc. for $35.1 million (closed 2024-07-09).
  - Action: disposition
  - Counterparty: Amylyx Pharmaceuticals, Inc.
  - Consideration: $35.1 million
  - Closing: 2024-07-09
  source text: the Company’s rights, title and interests in, to and under those assets and interests used by the Company in the development, manufacture and commercialization of Avexitide for $35.1 million, plus the aggregate amount of determined cure costs and assumed liabilities. At a hearing held on June 26, 2024, the Bankruptcy Court approved the sale of the Company’s Avexitide
  evidence_url: https://www.sec.gov/Archives/edgar/data/1305253/000119312524177016/0001193125-24-177016-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.